MX2022007220A - Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina. - Google Patents

Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.

Info

Publication number
MX2022007220A
MX2022007220A MX2022007220A MX2022007220A MX2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
antitrypsin deficiency
antitrypsin
deficiency
Prior art date
Application number
MX2022007220A
Other languages
English (en)
Inventor
James Andrew Huntington
Nigel Ramsden
David John Fox
James Michael Tomlinson
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Publication of MX2022007220A publication Critical patent/MX2022007220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de oxazol especificados de fórmula (1) y a composiciones farmacéuticas que contienen los compuestos. Los compuestos pueden ser inductores de ¿1-antitripsina (A1AT) y se pueden utilizar en el tratamiento contra una enfermedad o trastorno tal como la deficiencia de ¿1-antitripsina (A1AD o AATD).
MX2022007220A 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina. MX2022007220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1918416.7A GB201918416D0 (en) 2019-12-13 2019-12-13 Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
PCT/GB2020/053196 WO2021116710A1 (en) 2019-12-13 2020-12-11 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
MX2022007220A true MX2022007220A (es) 2022-09-07

Family

ID=69186871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007220A MX2022007220A (es) 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.

Country Status (13)

Country Link
US (1) US20230093755A1 (es)
EP (1) EP4073068B1 (es)
JP (1) JP2023506201A (es)
KR (1) KR20220127825A (es)
CN (1) CN115003669B (es)
AU (1) AU2020400334A1 (es)
BR (1) BR112022011564A2 (es)
CA (1) CA3164304A1 (es)
ES (1) ES2980046T3 (es)
GB (1) GB201918416D0 (es)
IL (1) IL293833A (es)
MX (1) MX2022007220A (es)
WO (1) WO2021116710A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
AU2019289228B2 (en) 2018-06-22 2024-11-14 Ucl Business Ltd Novel compounds
KR20210089656A (ko) 2018-10-05 2021-07-16 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 조절제
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina

Also Published As

Publication number Publication date
IL293833A (en) 2022-08-01
KR20220127825A (ko) 2022-09-20
GB201918416D0 (en) 2020-01-29
ES2980046T3 (es) 2024-09-27
US20230093755A1 (en) 2023-03-23
AU2020400334A1 (en) 2022-07-28
EP4073068B1 (en) 2024-04-24
WO2021116710A1 (en) 2021-06-17
BR112022011564A2 (pt) 2022-08-30
JP2023506201A (ja) 2023-02-15
CN115003669A (zh) 2022-09-02
CN115003669B (zh) 2024-10-25
EP4073068A1 (en) 2022-10-19
CA3164304A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX2023009856A (es) Dosificacion optimizada de diaminofenotiazinas en poblaciones.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
EA202090276A1 (ru) Фармацевтическая композиция для лечения анемии
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2022007219A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
IT201900021564A1 (it) Composizione nutraceutica o farmaceutica comprendente ferro pirofosfato per l’uso nel trattamento e/o nella prevenzione di condizioni o patologie caratterizzate da carenza di ferro
EP4393548A3 (en) Formulations and treatments employing hydroxypyridonate actinide/lanthanide decorporation agents
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
MX2022007220A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2021002936A (es) Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada.
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.